Charles River Laboratories

CRL

Market cap $8.77B

The small cap team initiated a new investment position in Hexcel Corporation. Hexcel is a global leader in advanced composite materials. We initiated a position in Charles River Labs in Q3. CRL is a high-quality company in the drug discovery and development outsourcing space. Small cap exited Saia this quarter. The company has faced a challenging macroeconomic environment for LTL (less-than-truckload) pricing.

Charles River Laboratories International, Inc. ( CRL ) Jefferies London Healthcare Conference 2025 November 18, 2025 6:30 AM EST Company Participants Birgit Girshick - Corporate Executive VP & COO Conference Call Participants David Windley - Jefferies LLC, Research Division Presentation David Windley Jefferies LLC, Research Division All right. Good morning, everybody.

STAMFORD, Conn.--(BUSINESS WIRE)--SOLVE, the leading provider of pre-trade data and predictive pricing for fixed income securities markets, today announced a new partnership with Charles River Development, a State Street company, to begin integrating SOLVE's fixed income and predictive pricing capabilities with the Charles River Investment Management Solution (Charles River IMS). The collaboration builds on SOLVE's mission to expand transparency across fixed income markets through advanced anal.

Explore how Charles River's (CRL) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories to Present at Jefferies Global Healthcare Conference.

Charles River Laboratories International, Inc. ( CRL ) Q3 2025 Earnings Call November 5, 2025 9:00 AM EST Company Participants Todd Spencer - Corporate Vice President of Investor Relations James Foster - Chairman, President & CEO Michael Knell - Interim CFO, Corporate Senior VP & Chief Accounting Officer Conference Call Participants Patrick Donnelly - Citigroup Inc., Research Division David Windley - Jefferies LLC, Research Division Elizabeth Anderson - Evercore ISI Institutional Equities, Research Division Eric Coldwell - Robert W. Baird & Co. Incorporated, Research Division Justin Bowers - Deutsche Bank AG, Research Division Casey Woodring - JPMorgan Chase & Co, Research Division Michael Ryskin - BofA Securities, Research Division Ann Hynes - Mizuho Securities USA LLC, Research Division Max Smock - William Blair & Company L.L.C.

Charles River Laboratories International Inc. (NYSE:CRL) stock is trading lower on Wednesday after the company released third-quarter 2025 earnings. It also provided an update on the company's strategic review.

Charles River Laboratories remains a "Hold" as strategic review yields minimal change and a sale is unlikely. CRL faces slow organic growth, shrinking backlog, and ongoing pressure in its core DSA segment, with limited near-term demand recovery. Cost-cutting, selective divestitures, and a new $1 billion buyback authorization offer some support, but growth headwinds persist.

While the top- and bottom-line numbers for Charles River (CRL) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Charles River beats Q3 profit and revenue forecasts but posts year-over-year declines and narrows its 2025 outlook.